Baseline characteristics of study population (N=4137)
| N (%) | SVR | NSVR | |
|---|---|---|---|
| Age (years) | |||
| ≤50 | 1318 (31.9) | 444 (34.3) | 874 (30.8) |
| >50 | 2819 (68.1) | 852 (65.7) | 1967 (69.2) |
| Gender | |||
| Male | 3972 (96.0) | 1233 (95.1) | 2739 (96.4) |
| Female | 165 (4.0) | 63 (4.9) | 102 (3.6) |
| Race | |||
| African-American | 798 (19.3) | 144 (11.1) | 654 (23.0) |
| Caucasian | 2808 (67.9) | 985 (76.0) | 1823 (64.2) |
| Others | 531 (12.8) | 167 (12.9) | 364 (12.8) |
| Ethnicity | |||
| Hispanic/Latino | 452 (10.9) | 124 (9.6) | 328 (11.5) |
| Not Hispanic/Latino | 3685 (89.1) | 1172 (90.4) | 2513 (88.5) |
| Body mass index (kg/m2) | |||
| <30 | 2674 (64.6) | 864 (66.8) | 1810 (63.7) |
| ≥30 | 1463 (35.4) | 432 (33.2) | 1031 (36.3) |
| ALT (IU/L) | |||
| ≤40 | 907 (21.9) | 320 (24.7) | 587 (20.7) |
| >40 | 3230 (78.1) | 976 (75.3) | 2254 (79.3) |
| Glucose (mg/dL) | |||
| <100 | 2269 (54.9) | 747 (57.6) | 1522 (53.6) |
| ≥100 | 1868 (45.1) | 549 (42.4) | 1319 (46.4) |
| HDL (mg/dL) | |||
| <40 | 1997 (48.3) | 665 (51.3) | 1332 (46.8) |
| ≥40 | 2140 (51.7) | 631 (48.7) | 1509 (53.2) |
| Triglyceride (mg/dL) | |||
| <150 | 2897 (70.0) | 948 (73.2) | 1949 (68.6) |
| ≥150 | 1240 (30.0) | 348 (26.8) | 892 (31.4) |
| Hypertension | |||
| Yes | 1043 (25.2) | 288 (22.2) | 755 (26.6) |
| No | 3094 (74.8) | 1008 (77.8) | 2086 (73.4) |
| FIB4-score | |||
| ≤3.25 | 3361 (81.2) | 1118 (86.3) | 2243 (79.0) |
| >3.25 | 776 (18.8) | 178 (13.7) | 598 (21.0) |
| Genotype | |||
| 1 | 3120 (75.4) | 704 (54.3) | 2416 (85.0) |
| 2 | 655 (15.8) | 391 (30.2) | 264 (9.3) |
| 3 | 362 (8.8) | 201 (15.5) | 161 (5.7) |
ALT, alanine transaminase; HDL, high-density lipoprotein; NSVR, non-SVR; SVR, sustained virological response.